Affiliation:
1. Aquapharm® Biodiscovery Ltd, European Centre for Marine Biotechnology, UK
Abstract
Over the last 20 years, the pharmaceutical industry has seen a decrease in discovery and success based on computational and combinatorial chemistry, and an increase in base costs imposed by increasing regulatory requirements and a higher rate of failures during the development process1. Couple this to the potential of structural, hence intellectual property overlap between libraries of synthetic compounds and the need for low-cost, scalable and chemically unique new scaffolds, the pharmaceutical industry is starting to re-evaluate the potential of natural products to provide the industry with new drug leads.
Subject
General Biochemistry, Genetics and Molecular Biology
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Marine natural products;Annual Reports Section "B" (Organic Chemistry);2013